These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 23339135)

  • 1. Imatinib-induced amelioration of neurologic deficits in a rare case of simultaneous association of missed multiple sclerosis and chronic myeloblastic leukemia.
    Siroos B; Harirchian MH; Abolfazli R
    Mult Scler; 2013 Aug; 19(9):1238-9. PubMed ID: 23339135
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib results in better outcomes than HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia.
    Jiang Q; Xu LP; Liu DH; Liu KY; Gale RP; Zhang MJ; Jiang B; Zhang XH; Wang Y; Chen SS; Zhao XY; Chen H; Jiang H; Chen YH; Han W; Qin YZ; Liu YR; Lai YY; Lv M; Huang XJ
    Leukemia; 2013 Dec; 27(12):2410-3. PubMed ID: 23698276
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical remission of Merkel cell carcinoma after treatment with imatinib.
    Loader DE; Feldmann R; Baumgartner M; Breier F; Schrama D; Becker JC; Steiner A
    J Am Acad Dermatol; 2013 Oct; 69(4):e181-3. PubMed ID: 24034390
    [No Abstract]   [Full Text] [Related]  

  • 4. Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia.
    Dika E; Barisani A; Vaccari S; Fanti PA; Ismaili A; Patrizi A
    J Drugs Dermatol; 2013 May; 12(5):512-3. PubMed ID: 23652942
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hypoprotidemia may explain imatinib intoxication in a patient with Philadelphia-positive acute lymphoblastic leukemia].
    Gaïes E; Trabelsi S; Sahnoun R; Salouage I; Jebabli N; Charfi R; Lakhal M; Hdiji S; Klouz A
    Therapie; 2013; 68(2):125-7. PubMed ID: 23773356
    [No Abstract]   [Full Text] [Related]  

  • 6. EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations.
    Bonifacio M; Binotto G; Calistri E; Maino E; Tiribelli M;
    Ann Hematol; 2014 Jan; 93(1):163-4. PubMed ID: 24292539
    [No Abstract]   [Full Text] [Related]  

  • 7. RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib.
    Lilljebjörn H; Ågerstam H; Orsmark-Pietras C; Rissler M; Ehrencrona H; Nilsson L; Richter J; Fioretos T
    Leukemia; 2014 Apr; 28(4):977-9. PubMed ID: 24186003
    [No Abstract]   [Full Text] [Related]  

  • 8. Leukocytosis: the mysteries within.
    Munoz J; Guo Y
    Am J Hematol; 2012 Feb; 87(2):197. PubMed ID: 21815181
    [No Abstract]   [Full Text] [Related]  

  • 9. Inimitable Imatinib: the range of targeted tumours expands to include T-cell lymphoma.
    Turner SD
    Leukemia; 2013 Apr; 27(4):759. PubMed ID: 23575607
    [No Abstract]   [Full Text] [Related]  

  • 10. p-Stat3 and bcr/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy.
    Sayed D; Badrawy H; Gaber N; Khalaf MR
    Leuk Res; 2014 Feb; 38(2):243-50. PubMed ID: 24374144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KIT mutations in a series of melanomas and their impact on treatment with imatinib.
    Botella-Estrada R; Soriano V; Rubio L; Nagore E
    Actas Dermosifiliogr; 2012 Nov; 103(9):838-40. PubMed ID: 22795573
    [No Abstract]   [Full Text] [Related]  

  • 12. Disparities in chronic myeloid leukemia survival by age, gender, and ethnicity in pre- and post-imatinib eras in the US.
    Mandal R; Bolt DM; Shah BK
    Acta Oncol; 2013 May; 52(4):837-41. PubMed ID: 23181388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment of unresectable dermatofibrosarcoma protuberans on finger with imatinib mesylate and Mohs microsurgery.
    Jeon IK; Kim JH; Kim SE; Kim SC; Roh MR
    J Dermatol; 2013 Apr; 40(4):288-9. PubMed ID: 23293988
    [No Abstract]   [Full Text] [Related]  

  • 14. [The effects of imatinib mesylate on immune globulin and T cell subset in patients with chronic myelocytic leukemia].
    Gui RR; Zhang YL; Fang BJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):225-6. PubMed ID: 22781613
    [No Abstract]   [Full Text] [Related]  

  • 15. The treatment of children suffering from chronic myelogenous leukemia: a comparison of the result of treatment with imatinib mesylate and allogeneic hematopoietic stem cell transplantation.
    Hamidieh AA; Ansari S; Darbandi B; Soroush A; Arjmandi Rafsanjani K; Alimoghaddam K; Bahosh G; Behfar M; Ghavamzadeh A
    Pediatr Transplant; 2013 Jun; 17(4):380-6. PubMed ID: 23551456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary validation of self-assessment tool to measure imatinib adherence in patients with chronic myeloid leukemia.
    Daouphars M; Ouvry M; Lenain P; Rouvet J; Jardin F; Bubenheim M; Varin R
    Pharmacotherapy; 2013 Feb; 33(2):152-6. PubMed ID: 23359430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of dasatinib in relapsed CNS, Ph+ ALL that is refractory to radiochemotherapy plus imatinib: a case report.
    Gutiérrez-Aguirre H; García-Rodríguez F; Cantú-Rodríguez O; González-Llano O; Jaime-Pérez J; Gómez-Almaguer D
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):875-8. PubMed ID: 22252621
    [No Abstract]   [Full Text] [Related]  

  • 18. A limited but necessary indication of stem cell transplantation for chronic myelogeneous leukemia in the era of tyrosine kinase inhibitors.
    Imataki O
    Transplantation; 2014 Jan; 97(1):e4-5. PubMed ID: 24374768
    [No Abstract]   [Full Text] [Related]  

  • 19. Cellular and molecular responses of Saudi chronic myeloid leukaemia patients to imatinib (STI-571): ten year experience.
    Alenzi FQ; Al-Amri AM; Alanazi FG; Tamimi W; Alanazi A; Alenezy AK; Al-Swailmi F
    J Ayub Med Coll Abbottabad; 2012; 24(2):122-8. PubMed ID: 24397072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.
    Pfeifer H; Wassmann B; Bethge W; Dengler J; Bornhäuser M; Stadler M; Beelen D; Vucinic V; Burmeister T; Stelljes M; Faul C; Dreger P; Kiani A; Schäfer-Eckart K; Schwerdtfeger R; Lange E; Kubuschok B; Horst HA; Gramatzki M; Brück P; Serve H; Hoelzer D; Gökbuget N; Ottmann OG;
    Leukemia; 2013 Jun; 27(6):1254-62. PubMed ID: 23212150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.